...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel
【24h】

Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel

机译:含紫杉醇水溶性前药的脂质体的制备,表征,细胞毒性和药代动力学

获取原文
获取原文并翻译 | 示例

摘要

Paclitaxel (Taxol) is a diterpenoid isolated from Taxus brevifolia, used clinically for the treatment of ovarian and breast cancer. Due to its aqueous insolubility it is administered dissolved in ethanol and Cremophor EL (polyethoxylated castor oil), which has serious side effects. In order to eliminate this vehicle, in previous work we entrapped paclitaxel in conventional and in polyethylene glycol coated liposomes. However, in neither formulation did we obtain satisfactory entrapment efficiency. In this study we increased the paclitaxel concentration entrapped in liposomes by incorporating different water-soluble prodrugs, such as the 2'-succinyl, 2'-methylpyridinium acetate and 2'-mPEG ester paclitaxel derivatives, in the lipid vesicles. Liposomes containing 2'-mPEG (5000)-paclitaxel showed the best performance in terms of stability, entrapment efficiency and drug concentration (6.5 mg ml(-1)). The in vitro cytotoxic activity of this liposomal prodrug was similar to that of the parent drug. The pharmacokinetic parameters for the fret: and for the liposomal prodrugs fitted a bi-exponential plasma disposition. The most important change in pharmacokinetic values of the prodrug vs. the free drug liposomal formulations was t(1/2)beta, plasma lifetime, which was longer in liposomes containing 2'-mPEG (5000)-paclitaxel. (C) 2000 Elsevier Science B.V. All rights reserved. [References: 49]
机译:紫杉醇(Taxol)是一种从短叶红豆杉(Taxus brevifolia)分离出的二萜类化合物,临床上用于治疗卵巢癌和乳腺癌。由于其在水中的不溶性,因此可以溶解在乙醇和Cremophor EL(聚乙氧基化蓖麻油)中溶解,这具有严重的副作用。为了消除这种载体,在以前的工作中,我们将紫杉醇包埋在常规的和聚乙二醇包衣的脂质体内。但是,在两种配方中均未获得令人满意的包封效率。在这项研究中,我们通过在脂质囊泡中掺入不同的水溶性前药(例如2'-琥珀酰基,2'-甲基吡啶鎓乙酸盐和2'-mPEG酯紫杉醇衍生物)来增加脂质体中捕获的紫杉醇浓度。含有2'-mPEG(5000)-紫杉醇的脂质体在稳定性,包封效率和药物浓度(6.5 mg ml(-1))方面表现出最佳性能。该脂质体前药的体外细胞毒性活性与母体药物相似。品格的药代动力学参数:和脂质体前药的药代动力学参数符合双指数血浆配置。前药相对于游离药物脂质体制剂的药代动力学值最重要的变化是t(1/2)β,血浆寿命,在含有2'-mPEG(5000)-紫杉醇的脂质体中更长。 (C)2000 Elsevier Science B.V.保留所有权利。 [参考:49]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号